2024-12-24 02:56:27
Author: Bactiguard Holding AB (publ) / 2023-07-23 23:33 / Source: Bactiguard Holding AB (publ)

New clinical trial shows 53% reduction of ventilator-associated pneumonia with Bactiguard's endotracheal tube

STOCKHOLM,Oct. 5,2021 -- This week at the European Society of Intensive Care congress (ESICM),a study from Liège,Belgium on Bactiguard's endotracheal tubes was presented. The study showed a 53% reduction in ventilator-associated pneumonia (VAP) in intensive care patients,intubated with Bactiguard's endotracheal tube with evacuation lumen (BIP ETT Evac).

"These data are of vital importance for critically ill patients across the world. Ventilator-associated pneumonia (VAP) is a feared complication with high mortality. The study data indicates that by using a Bactiguard endotracheal tube the risk of this deadly complication is significantly reduced",says Stefan Grass,Chief Medical Officer and Deputy CEO.

The study is a randomized-controlled study including 323 patients,either intubated with a Bactiguard endotracheal tube or a conventional tube (both with subglottic suctioning port). The number of VAP cases were 22.4 per 1000 ventilator days in the control group compared with 10.5 in the Bactiguard group which was just short of significance (p=0.07). The time to occurrence of VAP was significantly reduced in the Bactiguard group (p=0.02).

"During the COVID-19 pandemic there are multiple reports showing increased VAP rates in ICU patients and the use of our products can contribute to reducing these numbers. Actually,the study is called VITAL and the results proved to be just that",Stefan Grass concludes.

The VITAL study was selected as top 6 best abstracts at the ESICM congress. For registered ESICM delegates the poster can be found in the event platform: https://lives2021.e-lives.org/. Prof Misset is the presenter of the study.

About BIP Endotracheal Tube Evac

Bactiguard's BIP ETT Evac is the only tube on the market that combines the subglottic secretion drainage with the clinically proven ability of the Bactiguard technology to reduce microbial adhesion The technologyis based on a very thin noble metal alloy coating,firmly attached to the tube surface. When in contact with fluids,the noble metals create a galvanic effect which reduces microbial adhesion. This means that less bacteria adhere to the tube surface,which reduces the risk of biofilm formation leading to infection.

For more information,please contact:


Stefan Grass,Chief Medical Officer and Deputy CEO,mobile +46 70725 24 48

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/bactiguard-holding-ab--publ-/r/new-clinical-trial-shows-53--reduction-of-ventilator-associated-pneumonia-with-bactiguard-s-endotrac,c3427044

The following files are available for download:

https://mb.cision.com/Main/9686/3427044/1477031.pdf

211005 New clinical trial shows 53% reduction of ventilator-associated pneumonia with Bactiguard’s endotracheal tube

https://news.cision.com/bactiguard-holding-ab--publ-/i/bactiguard-bip-ett-evac,c2963668

Bactiguard BIP ETT Evac

Tags: Health Care/Hospital Medical Equipment Medical/Pharmaceuticals

Previous:

Next:

Leave a comment

CUSMail

CusMail provide the Latest News , Business and Technology News Release service. Most of our news is paid for distribution to meet global marketing needs. We can provide you with global market support.

© CUSMAIL. All Rights Reserved. Operate by Paid Release